Reviewing Globus Medical (NYSE:GMED) & Carmell (NASDAQ:CTCX)

Globus Medical (NYSE:GMED) and Carmell (NASDAQ:CTCX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Risk and Volatility

Globus Medical has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Globus Medical and Carmell, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0	3	8	0	2.73
Carmell	0	0	0	0	N/A

Globus Medical currently has a consensus price target of $77.20, suggesting a potential upside of 9.26%. Given Globus Medical’s higher probable upside, research analysts plainly believe Globus Medical is more favorable than Carmell.

Profitability

This table compares Globus Medical and Carmell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globus Medical	1.82%	8.70%	6.87%
Carmell	N/A	-148.47%	-40.47%

Institutional and Insider Ownership

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 24.2% of Carmell shares are owned by institutional investors. 18.5% of Globus Medical shares are owned by company insiders. Comparatively, 29.0% of Carmell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Globus Medical and Carmell”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.24 billion	4.28	$122.87 million	$0.64	110.41
Carmell	$12,320.00	666.98	-$15.44 million	N/A	N/A

Globus Medical has higher revenue and earnings than Carmell.

Summary

Globus Medical beats Carmell on 9 of the 11 factors compared between the two stocks.

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.